Cantor Fitzgerald Weighs in on Actinium Pharmaceuticals, Inc.'s FY2024 Earnings (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM - Free Report) - Analysts at Cantor Fitzgerald lifted their FY2024 earnings per share (EPS) estimates for Actinium Pharmaceuticals in a note issued to investors on Monday, April 1st. Cantor Fitzgerald analyst K. Kluska now expects that the biotechnology company will earn ($1.84) per share for the year, up from their previous estimate of ($2.14). Cantor Fitzgerald currently has a "Overweight" rating and a $21.00 target price on the stock. The consensus estimate for Actinium Pharmaceuticals' current full-year earnings is ($1.97) per share.

A number of other analysts have also recently weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Actinium Pharmaceuticals in a research report on Monday. Maxim Group upped their price target on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a "buy" rating in a research report on Tuesday, March 19th. B. Riley lowered their price target on Actinium Pharmaceuticals from $20.00 to $16.00 and set a "buy" rating on the stock in a research report on Monday, December 11th. Finally, StockNews.com cut Actinium Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Tuesday, March 19th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $25.72.

Actinium Pharmaceuticals Trading Up 2.5 %

Shares of ATNM traded up $0.22 on Thursday, reaching $9.06. 392,367 shares of the stock traded hands, compared to its average volume of 323,763. The stock has a market cap of $266.36 million, a PE ratio of -4.95 and a beta of 0.01. Actinium Pharmaceuticals has a 12 month low of $4.00 and a 12 month high of $9.86.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. UBS Group AG lifted its stake in Actinium Pharmaceuticals by 76.2% in the fourth quarter. UBS Group AG now owns 3,235 shares of the biotechnology company's stock valued at $34,000 after buying an additional 1,399 shares during the period. Royal Bank of Canada lifted its stake in Actinium Pharmaceuticals by 38.5% in the second quarter. Royal Bank of Canada now owns 6,734 shares of the biotechnology company's stock valued at $49,000 after buying an additional 1,871 shares during the period. California State Teachers Retirement System acquired a new position in Actinium Pharmaceuticals in the second quarter valued at about $64,000. The Manufacturers Life Insurance Company acquired a new position in Actinium Pharmaceuticals in the second quarter valued at about $83,000. Finally, Deutsche Bank AG increased its holdings in shares of Actinium Pharmaceuticals by 673.4% in the third quarter. Deutsche Bank AG now owns 15,235 shares of the biotechnology company's stock worth $90,000 after acquiring an additional 13,265 shares in the last quarter. Institutional investors and hedge funds own 27.50% of the company's stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.